Tilray is also a pot stock that probably isn't going to be generating a recurring profit for years. The company will likely devote a lot of its spending to capacity expansion, brand building, marketing, medical research and development, expansion into international markets, and acquisitions. Even with rapid sales growth, expenditures should tower over gross profit. That's not a good thing, given that operating results actually matter now that pot is legal in Canada.